BeOne

An arrow incrementally going up stairs before pointing straight up Blue background
Biotech

BeOne asset hits primary endpoint, tees up blood cancer filings

The trial of sonrotoclax hit its primary endpoint, furthering BeOne’s plans to launch the first BCL2 inhibitor for use in mantle cell lymphoma.
Nick Paul Taylor Aug 29, 2025 9:50am
parachutes sky italy sun blue

Pfizer’s reputation wrangler plans departure—Chutes & Ladders

Jul 11, 2025 8:30am
human brain abstract art

Novartis inks $175M option deal for Sironax’s BBB tech

Jul 9, 2025 10:29am
stop shut down close end button

BeiGene drops TIGIT drug over poor phase 3 lung cancer prospects

Apr 3, 2025 8:05am
graphic image of different colored hands shaking

BeiGene, Brii and Ideaya ring in 2025 with deals

Jan 2, 2025 8:30am
pay deal hand over cash licensing transaction money

BeiGene inks $150M deal to follow cancer trail blazed by Amgen

Dec 13, 2024 9:11am